The historical rank and industry rank for Hester Biosciences's FCF Margin % or its related term are showing as below:
BOM:524669'
s FCF Margin % Range Over the Past 10 Years
Min: -37.02 Med: 7.95 Max: 14.12
Current: 13.92
During the past 13 years, the highest FCF Margin % of Hester Biosciences was 14.12%. The lowest was -37.02%. And the median was 7.95%.
BOM:524669's FCF Margin % is ranked better than 79.17% of 960
companies
in the Drug Manufacturers industry
Industry Median: 2.48
vs BOM:524669: 13.92
Hester Biosciences FCF Margin % Related Terms
Hester Biosciences FCF Margin % Historical Data
* Premium members only.
The historical data trend for Hester Biosciences's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hester Biosciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hester Biosciences FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hester Biosciences's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Hester Biosciences's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hester Biosciences (BOM:524669) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Hester Biosciences and its competitors. According to the industry distribution chart, Hester Biosciences ranks #200 out of 960 companies in the Drug Manufacturers industry, placing it in the top 20.8%.
Is Hester Biosciences' FCF Margin % too high?
Hester Biosciences' current FCF Margin % is 0.00%. Based on the distribution chart, Hester Biosciences ranks #200 out of 960 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hester Biosciences has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hester Biosciences' FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hester Biosciences ranks #200 out of 960 companies for FCF Margin %. This places Hester Biosciences in the top 21% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.48, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Hester Biosciences and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hester Biosciences's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hester Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Hester Biosciences (BOM:524669) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,885.73, compared to a current price of ₹2,193.45 — trading 16.3% above its estimated fair value. The current FCF Margin % is 0.00%. Hester Biosciences' overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Hester Biosciences (BOM:524669), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hester Biosciences (BOM:524669) Overvalued in 2026?
Based on GuruFocus' analysis, Hester Biosciences stock appears to be overvalued.
The current stock price of ₹2,193.45 is trading 16.3% above its estimated GF Value™ of ₹1,885.73.
GuruFocus considers Hester Biosciences to be Modestly Overvalued.
Key valuation signals for BOM:524669:
FCF Margin %: 0.00%
GF Value™: ₹1,885.73 vs. price of ₹2,193.45 (16.3% above fair value)
No single metric tells the full story. See the BOM:524669 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hester Biosciences Ltd is an India-based animal healthcare company. It is principally engaged in the manufacturing of veterinary vaccines and trading of veterinary health products such as goat pox vaccine, PPR vaccines, etc. The group has two principal operating and reporting segments, viz. Poultry healthcare and Animal healthcare. Maximum revenue is generated from the Poultry Healthcare segment, which offers various solutions encompassing vaccines, health products, and feed supplements, supported and packaged by its diagnostic services, R&D, quality standards, and field support, to help farmers protect flock health, enhance productivity, and drive long-term farm sustainability. Geographically, it generates maximum revenue within India, and also exports its products to other markets.
73GF Score
Get the complete analysis for BOM:524669
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524669 has been successfully added to your 
